Posts Tagged ‘clinical trials’

In 2015, companies in all industries experienced data security breaches. From Anthem, one of the nation’s leading health benefits companies, to the UCLA Health System, all the way to Hzone, a matchmaking mobile application for HIV positive singles, no company was safe from a data breach. Increasing data privacy and security is a trend that […]

  Demographics in clinical trials have always been scrutinized by the medical community and the public. Are various races, ethnicities, sexes, and ages fairly represented in trials? Does one segment respond better or worse than another to a particular treatment? These questions and more are being answered in the Drug Trials Snapshots section of the […]

  In a time when the turnover rate for clinical monitoring positions in the U.S. hovers around 25%, it’s more important than ever to do more with less. With risk-based monitoring (RBM), contract research organizations (CROs) and sponsors can leverage data in existing IT systems to spot, rectify, and prevent issues related to the execution […]

  Real-world data, the data generated about drugs and devices in real-world settings (e.g., routing doctor visits, hospital stays, etc.), can help develop more accurate product profiles. This is because the data comes from products that are no longer confined to the smaller, homogenous populations involved in clinical trials. More comprehensive profiles can help better […]

  In my tenure here at Perficient, I’ve contributed to a number of guides for the life sciences industry. Each one has been informative and useful, but I can’t remember ever being as excited about any of them as I am about the newest one: Life Sciences is Going Digital. 

  Now that April is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in March – they’re ranked in order of popularity, with number one being the most viewed piece. 

  At the end of 2015, Austin Frakt, a health economist, researcher, and contributor to The New York Times’ The Upshot, wrote about the life sciences industry’s lack of interest in developing medicines that prevent cancer. 

Medication non-adherence continues to be a big issue in the pharma industry, affecting clinical outcomes for both approved and investigational drugs. Sponsors, research organizations, and payers are looking to verify that what they’re studying or paying for is actually being used as directed. Various technologies, such as Proteus and AiCure, are being examined for these […]

  As we mentioned in our life sciences trends guide for 2016, patient recruitment is a constant challenge that needs to be confronted head-on with innovative tactics and technology. The mere fact that only 5% of cancer patients ever enroll in a trial is simply unacceptable, considering how connected we are in the digital era. 

  If you’re a follower of our blog, you probably know that I enjoy listening to earnings conference calls. They give you a rare look into a company’s operational successes, and sometimes failures. Just last month, Quintiles held their Q4 2015 Earnings Call, which was full of information that gives color not only to the […]

  It’s that time of year again. The event for industry thought leaders and decision makers is just around the corner, and we’re hoping you’ll attend. Even if you can’t attend, we’re still giving you the opportunity to enter to win a SONOS wireless speaker…just because we like you. 

  On Tuesday, March 1, 2016, after being very ill for several days, I asked my husband to take me to the emergency room. I had been unable to keep food or drink down, and I had a very painful swollen mass in the right side of my neck/throat. In the ER, they determined that […]